Medications

Effectiveness of a new bladder cancer treatment demonstrated

Researchers from the Molecular Cancer group at the Hospital del Mar Medical Research Institute (IMIM) and doctors from Hospital del Mar, have demonstrated the effectiveness of a drug for treating metastatic bladder cancer ...

Oncology & Cancer

Synonymous genetic alterations: Not 'silent' at all

The so-called "silent" or "synonymous" genetic alterations do not result in altered proteins. But they can nevertheless influence numerous functions of the cell and thus also disease processes. Scientists from the German ...

Oncology & Cancer

FDA approves personalized therapy for metastatic bladder cancer

(HealthDay)—The first personalized treatment for patients with metastatic bladder cancer and susceptible fibroblast growth factor receptor (FGFR) genetic alterations was granted accelerated approval by the U.S. Food and ...

Medical research

DF-PGT, now possible through massive sequencing techniques

A research team from the Universitat Autònoma de Barcelona (UAB), in collaboration with the Blood and Tissue Bank of Catalonia, has implemented a massive sequencing platform for preimplantation genetic testing (PGT) for ...

Oncology & Cancer

A novel data-driven method to personalize cancer treatment

Identifying and prioritizing treatment options based on a patient's profile of genetic alterations is a major challenge in personalized cancer medicine. A new data-driven approach called PanDrugs can help to this end. This ...

Oncology & Cancer

Vigil immunotherapy tolerated well for recurrent ovarian CA Tx

(HealthDay)—Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a significant role in survival for ovarian cancer, according to ...

page 8 from 19